James Basta Net Worth

The estimated Net Worth of James Basta is at least $3.83 Million dollars as of 1 March 2024. Mr. Basta owns over 2,297 units of Kura Oncology Inc stock worth over $1,621,631 and over the last 5 years he sold KURA stock worth over $277,960. In addition, he makes $1,933,830 as Chief Legal Officer and Secretary at Kura Oncology Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Basta KURA stock SEC Form 4 insiders trading

James has made over 4 trades of the Kura Oncology Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 2,297 units of KURA stock worth $75,778 on 1 March 2024.

The largest trade he's ever made was selling 3,805 units of Kura Oncology Inc stock on 3 January 2024 worth over $112,095. On average, James trades about 925 units every 47 days since 2019. As of 1 March 2024 he still owns at least 81,571 units of Kura Oncology Inc stock.

You can see the complete history of Mr. Basta stock trades at the bottom of the page.

James Basta biography

James Basta J.D. serves as Chief Legal Officer and Secretary of the Company. Prior to joining us, from 2006 to November 2019, he served in roles of increasing responsibility at Biogen, Inc., a publicly-held biopharmaceutical company, most recently as Senior Vice President, Chief Corporation Counsel, where he managed the legal representation for Biogen’s securities filings, board of directors, business development, finance and tax, corporate affairs, employment and information technology. Prior to joining Biogen in 2006, he was Partner at Baker & McKenzie LLP. Mr. Basta earned his J.D. from Northwestern University School of Law and his B.A. in Economics from Northwestern University.

What is the salary of James Basta?

As the Chief Legal Officer and Secretary of Kura Oncology Inc, the total compensation of James Basta at Kura Oncology Inc is $1,933,830. There are 3 executives at Kura Oncology Inc getting paid more, with Kathleen Ford having the highest compensation of $3,485,030.

How old is James Basta?

James Basta is 54, he's been the Chief Legal Officer and Secretary of Kura Oncology Inc since 2019. There are 6 older and 13 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.

What's James Basta's mailing address?

James's mailing address filed with the SEC is C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE, MA, 02139.

Insiders trading at Kura Oncology Inc

Over the last 6 years, insiders at Kura Oncology Inc have traded over $16,903,587 worth of Kura Oncology Inc stock and bought 50,000 units worth $575,000 . The most active insiders traders include Faheem Hasnain, Troy Edward Wilson, and Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of $626,260. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth $57,922.

What does Kura Oncology Inc do?

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.

Complete history of Mr. Basta stock trades at Intellia Therapeutics Inc and Kura Oncology Inc

Kura Oncology Inc executives and stock owners

Kura Oncology Inc executives and other stock owners filed with the SEC include:

• Kathleen Ford,
  Chief Operating Officer
• Troy Wilson,
  Chairman of the Board, President, Chief Executive Officer
• Marc Grasso,
  Chief Financial Officer and Chief Business Officer
• James Basta,
  Chief Legal Officer and Secretary
• Dr. Troy Edward Wilson,
  Chairman, CEO & Pres
• Dr. Troy Edward Wilson J.D., Ph.D.,
  Chairman, CEO, Pres & Principal Financial Officer
• Dr. Marc Grasso,
  CFO & Chief Bus. Officer
• Kathleen Ford,
  Chief Operating Officer
• Kirsten Flowers,
  Chief Commercial Officer
• Dr. Marc Grasso M.D.,
  Advisor
• Dr. Stephen Dale M.D.,
  Chief Medical Officer
• Diane Parks,
  Independent Director
• Robert Hoffman,
  Independent Director
• Faheem Hasnain,
  Lead Independent Director
• Thomas Malley,
  Independent Director
• Steven Stein,
  Independent Director
• Mary Szela,
  Independent Director
• Bridget Martell,
  Acting Chief Medical Officer
• Kirsten Flowers,
  Chief Commercial Officer
• Stephen Dale,
  Chief Medical Officer
• Thomas Doyle,
  Principal Accounting Officer & Sr. VP of Fin. and Accounting
• Dr. Nic G. Scalfarotto,
  Sr. VP of Regulatory Affairs
• Dr. Roger Bakale Ph.D.,
  VP and Head of CMC, Clinical & Commercial Manufacturing
• Teresa Brophy Bair Esq., J.D.,
  Chief Legal Officer & Corp. Sec.
• James E. Basta J.D., Esq.,
  Chief Compliance Officer & Corp. Sec.
• Pete De Spain,
  VP of Investor Relations & Corp. Communications
• Teresa Brophy Bair,
  Chief Legal Officer
• Antonio Gualberto,
  Head of Development & CMO
• Pingda Ren,
  SVP Chemistry&Pharma Sciences
• Annette North,
  SVP, General Counsel
• Carol Schafer,
  
• Helen Louise Collins,
  
• Brian T. Powl,
  Chief Commercial Officer
• Thomas James Doyle,
  SVP, Finance & Accounting